These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24406339)

  • 21. Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
    Barros JI; Fechine FV; Montenegro Júnior RM; Vale OC; Fernandes VO; Souza MH; Cunha GH; Moraes MO; d'Alva CB; Moraes ME
    Arq Bras Endocrinol Metabol; 2014 Jun; 58(4):369-76. PubMed ID: 24936731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
    Hu J; Wang F; Sun R; Wang Z; Yu X; Wang L; Gao H; Zhao W; Yan S; Wang Y
    Endocrine; 2014 Mar; 45(2):279-87. PubMed ID: 23686639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
    Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
    Hao S; Sun J; Tian X; Sun X; Zhang Z; Gao Y
    J Pharm Pharmacol; 2014 Aug; 66(8):1133-9. PubMed ID: 24628303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G; Ragonesi PD; Fogari E; Cicero AF; Bianchi L; Bonaventura A; Romano D; Maffioli P
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?
    Hemmeryckx B; Hoylaerts MF; Gallacher DJ; Rong Lu H; Himmelreich U; D'hooge J; Swinnen M; Lijnen HR
    Eur J Pharmacol; 2013 Jan; 700(1-3):23-31. PubMed ID: 23228931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin.
    Manaer T; Yu L; Zhang Y; Xiao XJ; Nabi XH
    J Ethnopharmacol; 2015 Jul; 169():269-74. PubMed ID: 25922265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
    Okada K; Yagyu H; Kotani K; Yamazaki H; Ozaki K; Takahashi M; Nagashima S; Osuga J; Ishibashi S
    Endocr J; 2013; 60(7):913-22. PubMed ID: 23574730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sitagliptin (Januvia) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
    [No Abstract]   [Full Text] [Related]  

  • 30. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J; Faust M
    Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract]   [Full Text] [Related]  

  • 33. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sitagliptin beyond glycemic control: focus on quality of life.
    Sakamoto Y; Oyama J; Ikeda H; Kuroki S; Gondo S; Iwamoto T; Uchida Y; Kodama K; Hiwatashi A; Shimomura M; Taguchi I; Inoue T; Node K;
    Cardiovasc Diabetol; 2013 Feb; 12():35. PubMed ID: 23432786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function.
    Basu R; Oudit GY; Wang X; Zhang L; Ussher JR; Lopaschuk GD; Kassiri Z
    Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2096-108. PubMed ID: 19801494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
    Ferreira L; Teixeira-de-Lemos E; Pinto F; Parada B; Mega C; Vala H; Pinto R; Garrido P; Sereno J; Fernandes R; Santos P; Velada I; Melo A; Nunes S; Teixeira F; Reis F
    Mediators Inflamm; 2010; 2010():592760. PubMed ID: 20652060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T; Pyon EY
    Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
    Green J; Feinglos M
    Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.